Nephroangiosclerosis and its pharmacological approach.
Nephroangiosclerosis (NAS) is a major cause of progressive renal insufficiency. Hypertension is very important in the causation of NAS but other factors such as race, age, metabolic variables, and genetics play a pathogenic and prognostic role. A multifactorial treatment strategy, including antihypertensive, lipid-lowering and anti-platelet agents, could improve cardiovascular and renal outcomes in patients with vascular nephropathy.
Cianci
Rosario
R
Department of Nephrology, Sapienza University of Rome, Viale del Policlinico 155, Rome, Italy. ciancirosario@tin.it
Barbano
Biagio
B
Martina
Paola
P
Gigante
Antonietta
A
Polidori
Lelio
L
Lai
Silvia
S
Ascoli
Giada
G
De Francesco
Irene
I
Di Donato
Domenico
D
Fuiano
Giorgio
G
Zuccalà
Alessandro
A
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics / Q000503:physiopathology; D050197:Atherosclerosis / Q000503:physiopathology; D050171:Dyslipidemias / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics / Q000503:physiopathology; D009400:Nephrosclerosis / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors